Il-17 antibody formulation

The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing sp...

Full description

Saved in:
Bibliographic Details
Main Authors CORVARI VINCENT JOHN, WILLIAMS BARBARA ANN, DONOVAN PATRICK DANIEL, MARKHAM AARON PAUL
Format Patent
LanguageEnglish
Published 28.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
Bibliography:Application Number: NZ20130627648